CliffBio
small molecule

AMLODIPINE BESYLATE AND VALSARTAN

AMLODIPINE BESYLATE; VALSARTAN

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMLODIPINE BESYLATE AND VALSARTAN
Active ingredientAMLODIPINE BESYLATE; VALSARTAN
StrengthEQ 10MG BASE;320MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2015
Marketing statusDISCN

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.